BRAINSTORM CELL THERAPEUTICS (BCLI) Earnings History & Surprises
NASDAQ:BCLI • US10501E3009
1.17 USD
-0.03 (-2.5%)
At close: Jul 17, 2025
0.67 USD
-0.5 (-42.74%)
After Hours: 7/17/2025, 8:04:41 PM
Past quarterly earnings results for BRAINSTORM CELL THERAPEUTICS (BCLI), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateAug 12, 2025
PeriodQ2 / 2025
EPS Estimate-$0.38
Revenue Estimate
Last Reported
Release DateMay 15, 2025
PeriodQ1 / 2025
EPS Reported-$0.45
EPS Surprise 54.52%
Revenue Surprise %
Beat Rate
0%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2025 | -0.45 | -0.99 | 54.52% | 40.00% | - | - | ||
| Q4 2024 | -0.51 | -0.39 | -31.58% | -233.33% | - | - | ||
| Q3 2024 | -0.51 | -0.59 | 13.04% | -264.29% | - | - | ||
| Q2 2024 | -0.60 | -0.54 | -12.04% | 85.19% | - | - | ||
| Q1 2024 | -0.75 | -1.07 | 29.97% | 64.29% | - | - | ||
| Q4 2023 | -0.15 | - | 92.15% | - | - | |||
| Q3 2023 | -0.14 | -0.14 | 1.96% | 95.09% | - | - | ||
| Q2 2023 | -4.05 | -2.30 | -76.47% | -42.11% | - | - | ||
| Q1 2023 | -2.10 | -2.52 | 16.82% | 6.67% | - | - | ||
| Q4 2022 | -1.95 | -2.22 | 12.10% | 23.53% | - | - | ||
| Q3 2022 | -2.85 | -2.75 | -3.49% | -26.67% | - | - | ||
| Q2 2022 | -2.85 | -2.24 | -27.00% | -11.76% | - | - | ||
| Q1 2022 | -2.25 | -1.99 | -13.12% | 21.05% | - | - | ||
| Q4 2021 | -2.55 | -3.01 | 15.26% | 54.05% | - | - | ||
| Q3 2021 | -2.25 | -3.14 | 28.26% | -7.14% | - | - | ||
| Q2 2021 | -2.55 | -3.01 | 15.26% | 32.00% | - | - | ||
| Q1 2021 | -2.85 | -3.98 | 28.36% | 40.62% | - | - | ||
| Q4 2020 | -5.55 | -6.66 | 16.61% | - | - | - | ||
| Q3 2020 | -2.10 | -3.98 | 47.21% | - | - | - | ||
| Q2 2020 | -3.75 | -3.98 | 5.73% | - | - | - | ||
| Q1 2020 | -4.80 | -3.44 | -39.43% | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
5.98%
Max EPS beat (4)
54.52%
Min EPS beat (4)
-31.58%
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
In the last 4 quarters, BCLI has beaten EPS estimates in 2 out of 4 releases
In the last 4 quarters, BCLI has beaten the EPS estimates by 6.0% on average.
BRAINSTORM CELL THERAPEUTICS / BCLI Earnings FAQ
When did BRAINSTORM CELL THERAPEUTICS (BCLI) report earnings last quarter?
BRAINSTORM CELL THERAPEUTICS (BCLI) last reported earnings on 5/15/2025.
Can you provide information on whether BRAINSTORM CELL THERAPEUTICS beat earnings estimates in the last quarter?
BRAINSTORM CELL THERAPEUTICS (BCLI) beat EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does BCLI stock beat earnings estimates?
In the last 4 quarters, BRAINSTORM CELL THERAPEUTICS (BCLI) has beaten EPS estimates in 2 out of 4 releases.